Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 30 Apr 2012 |
| Novo Nordisk A/S: Operating profit increased by 18% in the first quarter of 2012 | 27 Apr 2012 |
| Novo Nordisk A/S expects to elect new chairman in 2013 | 27 Apr 2012 |
| Novo Nordisk A/S - Share repurchase programme | 26 Apr 2012 |
| Novo Nordisk A/S : Novo Nordisk A/S - Reduction of the share capital | 23 Apr 2012 |